Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $25.70 Consensus Price Target from Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been assigned an average rating of “Hold” from the eleven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $25.70.

Several analysts have weighed in on EYPT shares. Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective on the stock. Royal Bank Of Canada reissued a “sector perform” rating and issued a $5.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, August 18th. Wall Street Zen upgraded Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Citigroup dropped their price target on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Finally, Weiss Ratings raised Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st.

Institutional Trading of Eyepoint Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. KBC Group NV bought a new position in shares of Eyepoint Pharmaceuticals in the 1st quarter worth about $29,000. Russell Investments Group Ltd. bought a new stake in Eyepoint Pharmaceuticals during the third quarter worth about $76,000. Tower Research Capital LLC TRC boosted its stake in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after acquiring an additional 5,967 shares in the last quarter. California State Teachers Retirement System grew its holdings in Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the period. Finally, Persistent Asset Partners Ltd bought a new position in shares of Eyepoint Pharmaceuticals during the fourth quarter valued at approximately $98,000. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ:EYPT opened at $4.58 on Friday. The company has a 50-day moving average price of $10.79 and a 200-day moving average price of $12.79. The stock has a market cap of $394.84 million, a price-to-earnings ratio of -1.22 and a beta of 1.63. Eyepoint Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. Equities analysts forecast that Eyepoint Pharmaceuticals will post -3.51 EPS for the current fiscal year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.